# Lapatinib Ditosylate

## Tykerb 250mg

| 藥物代碼 | OTYK |
| :--- | :--- |
| 適應症 | Hypersensitivity to lapatinib ditosylate or to any of the excipients of Tykerb |
| 副作用 | Anorexia, diarrhea, nausea, vomiting, rash, fatigue, dyspepsia, dry skin, stomatitis, constipation, abdominal pain, palmar-plantar erythrodysesthesia, mucosal inflammation, pain in extremity, back pain, insomnia, epistaxis, alopecia; decreased LVEF, nail disorders, headache. |
| 禁忌 | In combination w/ capecitabine for the treatment of patients w/ advanced/metastatic breast cancer whose tumours overexpress HER2 & who have received prior therapy including anthracycline, taxane & trastuzumab. In combination w/ letrozole for the treatment of post-menopausal women w/ hormone receptor positive metastatic breast cancer that overexpress HER2 receptor for whom hormonal therapy is indicated. |
| 藥物保存方式 | room temp. |
| 用法用量 | HER2 positive metastatic breast cancer 1,250 mg \(5 tab\) daily on days 1-21 continuously in combination w/ capecitabine. 2,000 mg/m2/day \(orally in 2 doses approx 12 hr apart\) on days 1-14 in a repeating 21-day cycle. Hormone receptor positive, HER2 positive metastatic breast cancer Recommended dose: 1,500 mg \(6 tab\) continuously in combination w/ letrozole. All doses to be given once daily as a single dose. |
| 肝功能異常 | 需 調 整 劑 量  severe hepatic impairment \(Child-Pugh class C\): consider dose reduction to 750 mg ORALLY once daily \(human epidermal receptor-2 \(HER2\) positive metastatic breast cancer\) or 1000 mg ORALLY once daily \(hormone receptor positive, HER2 positive breast cancer\) |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | N/A |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

